Ascendis Pharma A/S
ASND
$161.52
$7.094.59%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 106.24M | 185.39M | 63.58M | 38.75M | 104.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 106.24M | 185.39M | 63.58M | 38.75M | 104.10M |
| Cost of Revenue | 18.43M | 14.95M | 12.31M | 12.34M | 8.22M |
| Gross Profit | 87.80M | 170.44M | 51.27M | 26.41M | 95.88M |
| SG&A Expenses | 106.34M | 85.51M | 76.77M | 79.98M | 72.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 215.91M | 184.98M | 169.94M | 182.18M | 157.45M |
| Operating Income | -109.67M | 408.30K | -106.36M | -143.43M | -53.35M |
| Income Before Tax | -98.46M | -39.85M | -107.93M | -117.48M | -139.53M |
| Income Tax Expenses | 1.12M | 1.16M | 1.12M | 246.50K | 2.72M |
| Earnings from Continuing Operations | -99.58M | -41.01M | -109.06M | -117.73M | -142.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.58M | -41.01M | -109.06M | -117.73M | -142.25M |
| EBIT | -109.67M | 408.30K | -106.36M | -143.43M | -53.35M |
| EBITDA | -104.88M | 1.72M | -101.55M | -138.71M | -48.49M |
| EPS Basic | -1.66 | -0.69 | -1.90 | -2.05 | -2.50 |
| Normalized Basic EPS | -1.03 | -0.42 | -1.17 | -1.28 | -1.53 |
| EPS Diluted | -1.66 | -0.69 | -1.90 | -2.05 | -2.50 |
| Normalized Diluted EPS | -1.03 | -0.42 | -1.17 | -1.28 | -1.53 |
| Average Basic Shares Outstanding | 60.02M | 59.79M | 57.54M | 57.35M | 56.88M |
| Average Diluted Shares Outstanding | 60.02M | 59.79M | 57.54M | 57.35M | 56.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |